# Endocannabinoid System & GLP-1 Mental Health Evidence > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-receptor-agonists-mental-health-evidence/ > **Published:** 2026-03-04T02:53:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:01:02-04:00 > **Clinical Summary:** Explore GLP-1 receptor agonists mental health evidence and their potential impact on psychiatric disorders including schizophrenia and anxiety. --- #### Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were studied using genetic analysis to assess their causal effect on ten psychiatric conditions. The findings suggest these medications may influence risk for certain [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), though the specific direction and magnitude of effects varied across conditions. Patients using GLP-1 receptor agonists, including those managing weight or diabetes, should be aware that emerging evidence points to meaningful psychiatric implications worth discussing with their clinician. ### #27 Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study. **Citation:** Xiang Longgang et al. *Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.* International journal of molecular sciences. 2025. PMID: 40141382. **Study type:** Journal Article, Meta-Analysis  |  **Topic area:** Autism  |  **CED Score:** 10 Design: 6 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: -2 Why This Matters This Mendelian randomization study provides genetic evidence for potential causal relationships between GLP1RA exposure and reduced risk of multiple psychiatric disorders, which could justify [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) examining these agents as adjunctive treatments for conditions with limited therapeutic options. Given the expanding use of GLP1RAs for metabolic disease, establishing their neuropsychiatric effects is critical for understanding both potential therapeutic benefits and adverse outcomes in large patient populations. The identification of specific mental illnesses most responsive to GLP1RA signaling could enable precision medicine approaches and inform drug repurposing strategies for psychiatric management. **Quality Gate Alerts:** - Preclinical only **Abstract:** Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists may have potential benefits for mental illnesses. However, their exact effects remain unclear. This study investigated the causal relationship between glucagon-like peptide-1 receptor agonist (GLP1RA) and the risk of 10 common mental illnesses, including attention deficit and hyperactivity disorder, anorexia nervosa, anxiety disorder, autism spectrum disorder, bipolar disorder, major depressive disorder, post-traumatic stress disorder, schizophrenia, [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), and alcohol use disorder. We selected GLP1RA as the exposure and conducted a Mendelian randomization (MR) analysis. The cis-eQTLs of the drug target gene GLP1R, provided by eQTLGen, were used to simulate the pharmacological effects of GLP1RA. Type 2 diabetes and BMI were included as positive controls. Using data from both the Psychiatric Genomic Consortium and FinnGen, we conducted separate MR analyses for the same disease across these two independent databases. Meta-analysis was used to pool the results. We found genetic evidence suggesting a causal relationship between GLP1RA and a reduced risk of schizophrenia [OR (95% CI) = 0.84 (0.71-0.98), I2 = 0.0%, common effects model]. Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI. However, the findings of this study provide insufficient evidence to support a causal relationship between GLP1RA and other mental illnesses. Sensitivity analyses did not reveal any potential bias due to horizontal pleiotropy or heterogeneity in the above results (p > 0.05). This study suggests that genetically proxied activation of glucagon-like peptide-1 receptor is associated with a lower risk of schizophrenia. GLP1R is implicated in schizophrenia pathogenesis, and its agonists may exert potential benefits through weight management. Our study provides useful information for understanding the neuropsychiat Clinical Perspective This Mendelian randomization study provides intriguing genetic evidence that GLP1R agonists may have protective effects against several mental health conditions, potentially opening new therapeutic avenues beyond their established metabolic benefits. However, several important caveats warrant clinical caution: Mendelian randomization cannot definitively establish causality in individual patients, the findings are based on population-level genetic associations rather than mechanistic studies or clinical trials, and reverse causality remains a concern since mental illness itself can affect metabolic health and GLP1R signaling. Additionally, cannabis-using patients often have comorbid metabolic and psychiatric conditions that might theoretically benefit from GLP1R agonists, yet we currently lack evidence on how cannabis use modifies any potential psychiatric benefits of these medications. While these preliminary findings are encouraging for future research directions, clinicians should not yet consider GLP1R agonists as primary mental health interventions; instead, we should remain alert to the possibility of incidental psychiatric improvements in patients prescribed these drugs  |   |  Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40141382/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11942543/)[DOI ↗](https://doi.org/10.3390/ijms26062741) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System & GLP-1 Receptor Mental Health Evidence](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) Detailed exploration of GLP-1 receptor involvement in mental health disorders and [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) interactions. [Read More](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) [Endocannabinoid System & GLP-1 Receptors: Clinical Evidence](https://cedclinic.com/glucagon-like-peptide-1-receptor-agonists-mental-health-evidence/) Clinical data on GLP-1 receptor agonists and their therapeutic potential in mental health conditions. [Explore Clinical Evidence](https://cedclinic.com/glucagon-like-peptide-1-receptor-agonists-mental-health-evidence/) [Endocannabinoid System Clinical Research Guide](https://cedclinic.com/glp-1-receptor-agonists-mental-health-evidence-overview/) Comprehensive guide to [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on the endocannabinoid system and its relevance to mental health. [View Guide](https://cedclinic.com/glp-1-receptor-agonists-mental-health-evidence-overview/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%20%26%20GLP-1%20Mental%20Health%20Evidence&url=https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-evidence%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-evidence%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%20%26%20GLP-1%20Mental%20Health%20Evidence%20https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-evidence%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).